4//SEC Filing
MILESON GLENNA 4
Accession 0001209191-21-039627
CIK 0001620463other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 6:48 PM ET
Size
9.3 KB
Accession
0001209191-21-039627
Insider Transaction Report
Form 4
MILESON GLENNA
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2021-06-10−6,305→ 6,305 totalExercise: $1.35Exp: 2028-12-17→ Common Stock (6,305 underlying) - Award
Common Stock
2021-05-18$14.45/sh+1,554$22,455→ 83,519 total - Exercise/Conversion
Common Stock
2021-06-10$1.35/sh+6,305$8,512→ 89,824 total
Footnotes (4)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of October 2, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c).
- [F2]The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began October 2, 2020.
- [F3]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the initial public offering price from the issuer's initial public offering.
- [F4]The shares subject to the option fully vested on January 1, 2021.
Documents
Issuer
Athira Pharma, Inc.
CIK 0001620463
Entity typeother
Related Parties
1- filerCIK 0001822241
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 6:48 PM ET
- Size
- 9.3 KB